210 related articles for article (PubMed ID: 27715317)
1. Treatment of substance use disorders in schizophrenia.
Bennett ME; Bradshaw KR; Catalano LT
Am J Drug Alcohol Abuse; 2017 Jul; 43(4):377-390. PubMed ID: 27715317
[TBL] [Abstract][Full Text] [Related]
2. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations.
Ziedonis DM; Smelson D; Rosenthal RN; Batki SL; Green AI; Henry RJ; Montoya I; Parks J; Weiss RD
J Psychiatr Pract; 2005 Sep; 11(5):315-39. PubMed ID: 16184072
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders.
Barrowclough C; Haddock G; Tarrier N; Lewis SW; Moring J; O'Brien R; Schofield N; McGovern J
Am J Psychiatry; 2001 Oct; 158(10):1706-13. PubMed ID: 11579006
[TBL] [Abstract][Full Text] [Related]
4. Treatment of substance use disorders with co-occurring severe mental health disorders.
Murthy P; Mahadevan J; Chand PK
Curr Opin Psychiatry; 2019 Jul; 32(4):293-299. PubMed ID: 31157674
[TBL] [Abstract][Full Text] [Related]
5. Patterns of Substance Use During Cognitive Enhancement Therapy: An 18-Month Randomized Feasibility Study.
Eack SM; Hogarty SS; Bangalore SS; Keshavan MS; Cornelius JR
J Dual Diagn; 2016; 12(1):74-82. PubMed ID: 27089154
[TBL] [Abstract][Full Text] [Related]
6. The associations between substance use disorders, schizophrenia-spectrum disorders, and Axis IV psychosocial problems.
Compton MT; Weiss PS; West JC; Kaslow NJ
Soc Psychiatry Psychiatr Epidemiol; 2005 Dec; 40(12):939-46. PubMed ID: 16247563
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological treatment of schizophrenia and co-occurring substance use disorders.
Smelson DA; Dixon L; Craig T; Remolina S; Batki SL; Niv N; Owen R
CNS Drugs; 2008; 22(11):903-16. PubMed ID: 18840032
[TBL] [Abstract][Full Text] [Related]
8. Management of schizophrenia with substance use disorders.
Lybrand J; Caroff S
Psychiatr Clin North Am; 2009 Dec; 32(4):821-33. PubMed ID: 19944886
[TBL] [Abstract][Full Text] [Related]
9. A Therapeutic Relational Agent for Reducing Problematic Substance Use (Woebot): Development and Usability Study.
Prochaska JJ; Vogel EA; Chieng A; Kendra M; Baiocchi M; Pajarito S; Robinson A
J Med Internet Res; 2021 Mar; 23(3):e24850. PubMed ID: 33755028
[TBL] [Abstract][Full Text] [Related]
10. Novel antipsychotic medications and the treatment of comorbid substance abuse in schizophrenia.
Buckley PF
J Subst Abuse Treat; 1998; 15(2):113-6. PubMed ID: 9561949
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy of schizophrenia with comorbid substance use disorder--reviewing the evidence and clinical recommendations.
Wobrock T; Soyka M
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1375-85. PubMed ID: 18394768
[TBL] [Abstract][Full Text] [Related]
12. Management of comorbid bipolar disorder and substance use disorders.
Salloum IM; Brown ES
Am J Drug Alcohol Abuse; 2017 Jul; 43(4):366-376. PubMed ID: 28301219
[TBL] [Abstract][Full Text] [Related]
13. Treatment for outpatients with comorbid schizophrenia and substance use disorders: a review.
De Witte NA; Crunelle CL; Sabbe B; Moggi F; Dom G
Eur Addict Res; 2014; 20(3):105-14. PubMed ID: 24192558
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal Course of Clients With Co-occurring Schizophrenia-Spectrum and Substance Use Disorders in Urban Mental Health Centers: A 7-Year Prospective Study.
Drake RE; Luciano AE; Mueser KT; Covell NH; Essock SM; Xie H; McHugo GJ
Schizophr Bull; 2016 Jan; 42(1):202-11. PubMed ID: 26294706
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy for schizophrenia and co-occurring substance use disorders.
Green AI
Neurotox Res; 2007 Jan; 11(1):33-40. PubMed ID: 17449446
[TBL] [Abstract][Full Text] [Related]
16. Cognitive Enhancement Therapy in substance misusing schizophrenia: results of an 18-month feasibility trial.
Eack SM; Hogarty SS; Greenwald DP; Litschge MY; McKnight SA; Bangalore SS; Pogue-Geile MF; Keshavan MS; Cornelius JR
Schizophr Res; 2015 Feb; 161(2-3):478-83. PubMed ID: 25510926
[TBL] [Abstract][Full Text] [Related]
17. Treatment of adult patients with schizophrenia and complex mental health needs - A national clinical guideline.
Baandrup L; Østrup Rasmussen J; Klokker L; Austin S; Bjørnshave T; Fuglsang Bliksted V; Fink-Jensen A; Hedegaard Fohlmann A; Peter Hansen J; Kristine Nielsen M; Sandsten KE; Schultz V; Voss-Knude S; Nordentoft M
Nord J Psychiatry; 2016; 70(3):231-40. PubMed ID: 26328910
[TBL] [Abstract][Full Text] [Related]
18. Treatments for patients with dual diagnosis: a review.
Tiet QQ; Mausbach B
Alcohol Clin Exp Res; 2007 Apr; 31(4):513-36. PubMed ID: 17374031
[TBL] [Abstract][Full Text] [Related]
19. A clinical approach to the assessment and management of co-morbid eating disorders and substance use disorders.
Gregorowski C; Seedat S; Jordaan GP
BMC Psychiatry; 2013 Nov; 13():289. PubMed ID: 24200300
[TBL] [Abstract][Full Text] [Related]
20. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial.
Potvin S; Stip E; Lipp O; Elie R; Mancini-Marië A; Demers MF; Roy MA; Bouchard RH; Gendron A
Curr Med Res Opin; 2006 Jul; 22(7):1277-85. PubMed ID: 16834826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
